BioMarin Data Shows Early VOXZOGO Treatment Boosts Growth Outcomes in Achondroplasia
Event summary
- BioMarin presented new data at the 2026 ACMG meeting showing early VOXZOGO treatment improves proportionality, arm span, and BMI in children with achondroplasia.
- Children starting treatment before age 2 showed durable, multi-year growth improvements, including a 4.7 cm height gain after four years.
- Over 5,000 children across more than 50 countries have received VOXZOGO, with real-world evidence supporting its effectiveness in Japan, Europe, and the U.S.
- VOXZOGO is the only approved treatment for achondroplasia starting at birth, with over 10,000 patient-years of clinical evidence.
The big picture
BioMarin's latest data reinforces the strategic importance of early intervention in rare disease treatment, particularly in conditions like achondroplasia where skeletal development is critical. The company's focus on real-world evidence aligns with broader industry trends toward outcomes-based validation, potentially setting a new standard for pediatric rare disease therapies. With VOXZOGO's unique approval for infants, BioMarin is positioning itself as a leader in addressing unmet needs in skeletal dysplasia.
What we're watching
- Treatment Timing
- How the emphasis on early treatment will impact VOXZOGO's adoption and market penetration.
- Global Expansion
- Whether BioMarin can sustain real-world evidence momentum across diverse regions like Japan, Europe, and the U.S.
- Long-Term Efficacy
- The pace at which additional long-term data will solidify VOXZOGO's position as the leading achondroplasia treatment.
Related topics